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assess whether the drug costs stated in BIA matches to real costs. Methods: Twelve 
HID obtained CED in 2013. The drug costs were identified in BIA of eleven HID. Real 
costs of General Health Insurance Company (VZP) were found out for each HID in 
the first year of therapy. As VZP holds 60% of the health insurance market, the data 
were extrapolated to the whole population. The differences between estimated and 
real drug costs were analysed and a correlation between this differences and drug 
characteristics justifying their HID status were investigated. Results: The estimated 
costs were exceeded in five cases (overrun between 31-332%). In six cases real costs 
did not achieve the estimation (12-91% of estimated costs). Concerning effectiveness 
and safety characteristics of investigated drugs, within seven drugs granted as HID 
because of absence of an alternative drug, four exceeded the estimation. One of two 
drugs granted as HID because of adverse effects reduction compared with current 
treatment exceeded the estimation. Remaining two drugs did not achieve the estima-
tion, one was granted HID because of mortality reduction, another because of higher 
effectiveness compared with current treatment. ConClusions: However HID costs 
estimated in BIA are submitted in order to predict costs of public health insurance, 
the analysis did not prove their validity and contribution to a reasonable decision 
making. Despite the fact that BIA is a mandatory requirement and it is cost and time 
consuming, its role is formal only and its premises have neither practical impact nor 
they are subject of further review.
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objeCtives: To conduct a review of different stakeholders’ policies and perspectives 
on using Real-World Data (RWD) for early drug development and clinical effective-
ness assessment in order to shed light on the possibilities for the incorporation 
of RWD and Real-World Evidence (RWE) in both aspects. Methods: A qualitative 
methodology was selected that combines semi-structured interviews with a litera-
ture review. 19 stakeholders from 8 different stakeholder groups were interviewed. 
Meanwhile, a review of academic and grey literature was performed. Transcripts of 
interviews and data from review articles were subjected to coding analysis. Analysis 
focused on: definitions for RWD provided, current policies on RWD, context (actual 
& perceived) for RWD use, advantages and disadvantages of RWD, practical obsta-
cles to using RWD, and political and procedural implications for RWD incorpo-
ration. Results: Consensus regarding the definition of RWD and types of RWD 
was lacking among stakeholders. A current gap in policies addressing RWD also 
exists. Despite this, RWD is currently used for reimbursement, regulatory and drug 
development processes. RWD has high external validity & generalisability and can 
provide valuable data on long-term outcomes. Yet biases in data, poor data quality 
(completeness, comprehensiveness) and lack of standardisation entice scepticism 
for its use. Ambiguity still remains on governance of RWD/RWE as well as a cultural 
barrier among stakeholders against the use of RWD/RWE. ConClusions: Increased 
stakeholder collaboration is needed to harmonise definitions and evidence needs of 
RWD, reach consensus on the relevance of RWD for addressing specific questions, 
and to standardise RWD data collection and analysis methods.
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objeCtives: The term efficacy-effectiveness-gap refers to the difference between 
the outcomes received within randomized controlled trials and those observed 
in real-word clinical practice. The phenomenon is often described in literature 
whereas papers generally remain unassertive or unspecific. The objective of our 
paper is to give a summary of the literature regarding extent, causes and implica-
tions of the gap. Methods: A systematic review was undertaken. We searched 
PubMed, the Cochrane Library and Scopus for relevant articles. Papers assessing 
extent, causes and/or implications were included. Only full-papers in English or 
German language were eligible. Scanning reference lists, internet search and tar-
geted contact with experts complemented our search. Two authors independently 
reviewed titles, assessed articles’ eligibility for inclusion and extracted relevant 
data. Results: In total 650 studies were identified. 27 of them met the inclusion 
criteria. We found that causes were most often analyzed in literature. The causes 
most often mentioned include patient-related causes such as lack of adherence, 
but also health-system related, service-provider-related as well as disease- or drug-
related causes. 18 studies derived implications. Implications found predominantly 
focus on possibilities on how to bridge the gap. Only 5 articles address the extent 
of the gap whereof not a single one actually tried to quantify it. Instead, statements 
remain unassertive (“quite large”, “huge”, etc.) and results diverge regarding size as 
well as direction. ConClusions: While the causes of the gap seem to be relatively 
well understood, there is a lack of studies trying to analyze the actual extent of the 
gap. Authors encourage further research especially on approaches to quantify the 
extent of the gap.
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intRoduCtion: In Egypt, health insurance organization (HIO) was established 
since 1964 as the governmental health insurer for public servants. Since then, it 
has significantly grown both in coverage and services as it currently covers 58% of 
by The Federal Regulatory Agency for Private Health Insurance and Plans (ANS) in 
supplementary health sector. Methods: A comparative analysis between the LP 
7169/2014 and the NR 343/2013 (normative resolution that defines mediation rules 
in ANS currently) was made focusing on their similarities and differences. Results: 
According to the LP, mediation is an alternative way to solve controversies in pub-
lic administration. In supplementary health sector, the only way to have conflicts 
solved by ANS is through mediation. It’s not an option, but the first step to every 
patient complaint about its health plan. Another difference is about the mediation 
closing. The LP provides the autonomy of the parties while in ANS, the mediation 
is just closed when there’s no irregularities or when the problem is really solved 
by the health plan. The comparison allowed the identification of some common 
principles like equality, good faith, the search for consensus and neutrality of the 
mediator. ConClusions: The conflicts’ mediation in supplementary health sector 
is a successful experience developed by the ANS. It has some rules defined by the 
NR. The LP brings some other rules to the mediation of conflicts in the public admin-
istration. So, it’s possible to note that the mediation carried out by ANS nowadays 
is not fully suited to the Law Project. Maybe, the deeper knowledge of successful 
experiences in other countries, where the tool is more widespread, could guide the 
discussion about the improvement of the current LP and also point the best way to 
adapt the existing experiences in Brazil to the new legal provision.
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objeCtives: To identify the most used way to make complaints about health plans 
to The Federal Regulatory Agency for Private Health Insurance and Plans (ANS) in 
Brazil. Methods: A retrospective analysis of data was done to identify the most 
used channel of the three currently available: the personal, the call center and the 
electronic. Two different periods were considered to the study: the second semester 
of 2013 (the last one that still used an institutional email to the electronic com-
plaints) and the second semester of 2014 (after the creation of a specific form for 
complaints available on ANS website). Results: According to the data, the way 
most consumers choose to make a complaint is the call center (68,5% -2013 and 
71,7%-2014). The second one is the electronic way. Comparing the two periods of 
the study it’s possible to note a decrease of 5% in the use of electronic complaints 
after the form implementation (26% to 21%). The less used way is the personal one 
(6, 7% -2013 5,4%-2014). The study doesn’t point a clear relationship between the 
themes of the complaints and the kind of service used. ConClusions: The study 
showed the call center is the primary service used. The personal service is less 
used then the others, probably because it’s offered only in the biggest Brazilian 
cities. The implementation of the electronic form, through which the consumer 
can register and track their complaints, didn’t increase the use of this channel. It’s 
possible that form design, with required fields and limited number of characters, is 
acting like a complicating factor. As is known, the excessive work of the call center 
can compromise its quality and efficiency. So, it would be interesting to verify the 
key points to improve the electronic form to spread its use aiming to reduce costs 
through a future staff downsizing.
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objeCtives: In 2012 the Hungarian intensive care units system was restruc-
tured. The multidiscipline intensive care units were separated from the postop-
erative intensive units and the one specialty intensive units. The effect of it was 
analyzed. Methods: Data were got from the National Health Insurance Fund 
Administration of the intensive care units for 10 years. There were investigated 
the organizational and the patient care related data. Results: In 2012 the number 
of the multidiscipline intensive care units decreased 20% and the number of beds 
decreased 10%. Due to reorganization both the CMI and days of mechanical ventila-
tion increased significantly in the multidiscipline intensive care units. In 2000 the 
12% of the patients were discharged from the intensive care units to home, but by 
2014 this rate decreased to 3%. It showed the use of the intensive care units were 
partially unnecessary before the reorganization. If we take the optimal bed-usage 
for the intensive care units to be 85%, in the new situation the actually available 
reimbursement approached to the theoretical value. The average bed-usage was 
55% in the both period, but the statistical variance between the separated intensive 
care units decreased in the last years. ConClusions: The results shows that the 
reorganization was effective. Level of the intensive care have got higher, the use of 
the beds and the reimbursement increased. It is suggested to do similar reorganiza-
tions in the other specialties.
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objeCtives: The coverage with evidence development (CED) is a mode of reimburse-
ment intended for highly innovative drugs (HID) in the P&R system in the Czech 
Republic. Cost-effectiveness analysis and budget impact analysis (BIA) are mandatory 
requirements for setting the reimbursement. The objective of the present study was to 
